Today: 6 February 2026
Subscribe
Browse Category

CSE:NOVO-B News 11 December 2025 - 6 February 2026

Novo Nordisk stock rebounds as FDA warns on illegal Wegovy copycats

Novo Nordisk stock rebounds as FDA warns on illegal Wegovy copycats

Copenhagen, Feb 6, 2026, 10:56 CET — Regular session Novo Nordisk A/S shares climbed 4.7% in early trading on Friday after the U.S. Food and Drug Administration pledged to crack down on mass-marketing of unapproved drug copies. By 0848 GMT, the stock was up 4.9% at 294.50 Danish crowns. (Reuters) The bounce matters because the market has been trying to…
6 February 2026
····
Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Updated: December 14, 2025 (Sunday) Novo Nordisk A/S shares ended this week with a rebound after a choppy start, as investors weighed three heavyweight catalysts: (1) the EU regulator’s support for a higher-dose Wegovy, (2) the long-telegraphed India launch of Ozempic at a sharply lower price point, and (3) the closing of Novo’s multibillion-dollar acquisition of Akero Therapeutics to expand…
14 December 2025
·······
Novo Nordisk (NVO) Stock Today: Worst Year on Record, Fresh Downgrades – and a New 2026 Forecast (11 December 2025)

Novo Nordisk (NVO) Stock Today: Worst Year on Record, Fresh Downgrades – and a New 2026 Forecast (11 December 2025)

Novo Nordisk A/S – the Danish maker of Ozempic and Wegovy – is having the kind of year investors usually wake up from, not live through. On 11 December 2025, Novo Nordisk’s U.S.-listed ADRs (ticker NVO) trade around $49 per share, after a bounce of roughly 5–6% in recent sessions. Copenhagen-listed B‑shares sit near 316 DKK, yet they remain close…
11 December 2025
······

Stock Market Today

  • Dream Unlimited (TSE:DRM) Stock Falls Below 200-Day Moving Average Amid Analyst Upgrade
    February 6, 2026, 8:11 AM EST. Dream Unlimited Corp's (TSE:DRM) stock dipped below its 200-day moving average of C$19.67, touching C$19.64 on Thursday, signaling potential short-term weakness. Despite this, TD Securities raised their target price from C$27.00 to C$28.00, maintaining a buy rating. The company recently reported a quarterly loss of C$0.35 per share and a negative net margin of 4.18%, reflecting operational challenges. Dream Unlimited declared a quarterly dividend of C$0.1625, with an annualized yield of 3.3%. The real estate firm holds a market cap of roughly C$832 million and a price-to-earnings ratio of 10.84. Investors should note the stock's current trading dynamics and positive analyst outlook amid mixed financial results.
Go toTop